EQS-News: SCHOTT Pharma delivers strong second quarter of fiscal year 2025

SCHOTT Pharma delivers strong second quarter of fiscal year 2025

• Q2 2025 revenues up 8% yoy to EUR 252m; increase of 10% yoy at constant currencies
• Q2 2025 EBITDA margin of 28.6% as reported and 28.2% at constant currencies
• Share of strong-margin high-value solutions (HVS) at 56% in Q2 2025
• SCHOTT Pharma reaffirms FY 2025 guidance

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, today published its results for the second quarter of the fiscal year 2025¹. “Despite ongoing macroeconomic uncertainties and market volatility, we continue to see strong momentum in the long-term trends shaping the pharmaceutical industry. Our strong innovations and capacity expansions drive our growth, in both the core business and the high-value solution business. We are well on track to achieve our financial targets 2025,” said Andreas Reisse, CEO of SCHOTT Pharma.

“Following a softer start into the year, increased demand for high-value solutions and our ongoing cost savings led to a strong bottom-line performance in the second quarter. Our investments in expanding capacities and optimizing our portfolio provide a strong foundation for continued financial stability and growth,“ said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma.

 

Strong growth in revenues; positive mix shift led to significant increase in EBITDA

Revenues in Q2 2025 reached EUR 252m, reflecting a solid increase of 8% yoy as reported or an increase of 10% at constant currencies. The main driver for this growth was the high demand for strong-margin high-value solutions (HVS), in the Drug Containment Solution (DCS) segment across the board from ready-to-use (RTU) products to specialty vials. In addition, the ongoing strong demand for glass syringes in the Drug Delivery Systems (DDS) segment compensated for a temporary weaker demand for polymer syringes. 

SCHOTT Pharma’s EBITDA surged to EUR 72m, a significant increase of 63% yoy as reported. This strong increase was driven by a mix shift towards HVS and the continued execution of efficiency measures. In addition, last year’s Q2 experienced strong FX headwinds mainly from hedging totaling to 23m EUR. The FX effects in Q2 2025 were marginal. Consequently, EBITDA at constant currencies amounted to 72m EUR. EBITDA margin increased to 28.6%, which compares to a margin of 18.9% in Q2 2024. At constant currencies, the EBITDA margin in Q2 2025 stood at 28.2%. The positive impact of efficiency measures and HVS growth overcompensated the temporary underutilization in vial and polymer syringe capacities as well as the current ramp-up costs in Hungary and Serbia. The direct impact from US tariffs is expected to be limited. SCHOTT Pharma is well on track to achieve its fiscal year guidance. 

The DDS segment saw a continuous high demand for glass syringes. SCHOTT Pharma reports revenues of EUR 109m in Q2 2025, which presents an increase of 9% yoy. DDS EBITDA amounted to EUR 38m, only marginally below the very strong results from last year’s Q2. This figure includes ramp-up costs for further production capacities for prefillable glass syringes in Hungary.

In the DCS segment, revenues showed a strong 7% increase yoy to EUR 143m. This performance was specifically driven by the high demand for HVS such as sterile vials and cartridges as well as coated specialty vials. On the back of HVS growth and ongoing cost improvement measures, DCS EBITDA increased by 21% to EUR 33m and an improved margin.

 

Driving innovation across segments

SCHOTT Pharma continues to drive innovation with its SCHOTT TOPPAC® freeze polymer syringe, the first and only syringe on the market designed for ultra-low temperature storage at -180 °C. This product supports the safe storage of sensitive biologics, such as cell and gene therapies, advancing patient safety.

SCHOTT Pharma is also expanding its cartriQ^® portfolio with the launch of a 1.5 ml RTU cartridge, the smallest sterile format in its lineup, used for the safe storage of medications like insulin, GLP-1 drugs, and hormone therapies. Designed to meet the growing demand for efficient pharmaceutical manufacturing, the new small cartridge leverages an innovative diamond-shaped nest and helps pharmaceutical companies improve efficiency, reduce costs, and accelerate time-to-market for medications.

Additionally, through the “Alliance for RTU”, SCHOTT Pharma and its partners are promoting the market adoption of RTU solutions. This strategic network aims to enhance manufacturing efficiency and patient safety and is continuously growing.

 

Outlook

Based on the good developments in the first half of fiscal year 2025, SCHOTT Pharma is well on track to achieve its full year guidance of revenue growth in the high single digits as well as an EBITDA margin approximately at the high level of FY 2024 (both at constant currencies).

Looking ahead, the market demand might experience some short-term volatility due to macro-economic uncertainties. However, the long-term pharma trends remain intact and will drive SCHOTT Pharma’s main growth in the long-term.

 

For additional news about SCHOTT Pharma please visit our media center.

Key figures Q2 2025

(in EUR m)	Q2 24	Q2 25	Δ yoy	Q2 25 (cc2)	Δ yoy (cc2)
Revenues	234	252	8%	257	10%
DCS Revenues	134	143	7%	148	11%
DDS Revenues	100	109	9%	109	8%
Cons./Recon.	0	0	nm	0	nm
EBITDA	44	72	63%	72	64%
DCS EBITDA	28	33	21%	35	27%
DDS EBITDA	39	38	-3%	37	-3%
Cons./Recon.	-22	1	nm	0	nm
EBITDA margin	18.9%	28.6%	9.7pp	28.2%	9.3pp
DCS EBITDA margin	20.6%	23.3%	2.7pp	23.7%	3.0pp
DDS EBITDA margin	38.4%	34.4%	-4.0pp	34.3%	-4.1pp
EBIT	28	53	86%
EBIT margin	12.2%	21.0%	8.8pp
Earnings per share (in EUR)	0.17	0.26	54%
Cash flow from operating activities (A)	25	48	23
Cash flow from investing activities (B)	-29	-29	0
Free cash flow (A+B)	-3	19	22
Total cash CAPEX	28	30	-2

 

 

Key figures H1 2025

(in EUR m)	H1 24	H1 25	Δ yoy	H1 25 (cc2)	Δ yoy (cc2)
Revenues	466	482	3%	498	7%
DCS Revenues	263	272	3%	290	10%
DDS Revenues	204	211	3%	208	2%
Cons./Recon.	0	0	nm	0	nm
HVS revenue share	53%	55%	2pp
EBITDA	117	130	11%	136	16%
DCS EBITDA	54	62	13%	66	22%
DDS EBITDA	78	72	-8%	71	-10%
Cons./Recon.	-16	-3	nm	-1	nm
EBITDA margin	25.1%	26.9%	1.9pp	27.3%	2.2pp
DCS EBITDA margin	20.7%	22.6%	1.9pp	22.8%	2.1pp
DDS EBITDA margin	38.3%	34.1%	-4.3pp	33.9%	-4.4pp
EBIT	87	92	7%
EBIT margin	18.5%	19.1%	0.6pp
Earnings per share (in EUR)	0.46	0.45	-3%
Cash flow from operating activities (A)	91	72	-19
Cash flow from investing activities (B)	-57	-50	7
Free cash flow (A+B)	34	22	-12
Total cash CAPEX	57	51	-6

Differences in the total numbers in the tables may be due to rounding. / nm = not meaningful

¹The fiscal year runs from October to September. Q2 2025 therefore relates to the period from January 2025 to March 2025.
²CC = at constant currencies

 

Webcast

Andreas Reisse (CEO) and Dr. Almuth Steinkühler (CFO) will speak at an analyst and investor conference call at 11:00 a.m. CET on 15 May 2025 to discuss the Q2 2025 results. The audio webcast can be followed via a conference call. The accompanying presentation can also be downloaded on the IR website: www.schott-pharma.com/investor-relations  

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 25,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com

Press contact

Lea Kaiser

PR & Communications Manager

Tel.: +49 (0) 151 68917195

E-Mail : lea.kaiser@schott.com

 

Tobias Erfurth

Head of Investor Relations

E-Mail: ir.pharma@schott.com

 

Jasko Terzic, CFA

Senior Manager Investor Relations

E-Mail: ir.pharma@schott.com